PROTAGONIST THERAPEUTICS, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$7M
↓-95.6% -$163Mvs FY2024 (Q4)
Gross Profit
$7M
↓-95.6% -$163Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $7M | $171M |
| COGS | $0 | $0 |
| Gross Profit | $7M | $171M |
| R&D | $46M | $35M |
| SG&A | $0 | $0 |
| D&A | $376K | $118K |
| Other OpEx | $0 | $9M |
| Operating Income | $0 | $127M |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $127M |
| Tax | $0 | $2M |
| Net Income | $0 | $125M |
QuarterCharts · SEC EDGAR data · PTGX · Comparing FY2025 (Q4) vs FY2024 (Q4)